Choi Eugene A, Feig Barry W
Department of Surgical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA.
Curr Oncol Rep. 2007 Jul;9(4):303-8. doi: 10.1007/s11912-007-0037-9.
Gastrointestinal stromal tumors (GISTs) are rare mesenchymal tumors of the gastrointestinal tract. Traditionally, surgery has been the primary treatment modality for these tumors, with only modest results. The recent development of kinase inhibitors (most notably, imatinib mesylate) has provided a new paradigm for the treatment of this disease. Response rates approaching 60% have been seen in studies in patients with advanced disease. Previously, chemotherapy played little role in the treatment of this disease. Now, however, treatment with kinase inhibitors can increase the number of patients who may potentially benefit from surgical intervention. Many questions regarding the use of kinase inhibitors remain. Most importantly, the optimal duration of treatment before surgical intervention and following both complete and incomplete tumor resection remains to be elucidated. Ongoing prospective trials have the potential to provide some of these answers in the near future.
胃肠道间质瘤（GISTs）是胃肠道罕见的间充质肿瘤。传统上，手术一直是这些肿瘤的主要治疗方式，但效果有限。激酶抑制剂（最显著的是甲磺酸伊马替尼）的最新进展为这种疾病的治疗提供了新的模式。在晚期疾病患者的研究中，缓解率接近60%。以前，化疗在这种疾病的治疗中作用不大。然而现在，激酶抑制剂治疗可以增加可能从手术干预中获益的患者数量。关于激酶抑制剂的使用仍有许多问题。最重要的是，手术干预前以及肿瘤完全和不完全切除后的最佳治疗持续时间仍有待阐明。正在进行的前瞻性试验有可能在不久的将来提供其中一些答案。
